SI
SI
discoversearch

 Microcap & Penny Stocks | EXTI - only public co. developing liver device


Previous 10 | Next 10 
To: CENTrader who wrote (788)2/16/2000 7:40:00 PM
From: MaxLeverage
   of 1063
 
Not new , but noteworthy from Exten's site.

"The company expects to 1) directly sell devices to hospitals, particularly those with liver transplant programs and 2) set up freestanding outpatient treatment centers much like renal dialysis centers, so that patients can resist or overcome liver disease or poisoning by periodic or short-term treatments. 3) Sell international licensing agreements. The potential market for artificial liver support is projected to be hundreds of millions of dollars annually in the US alone. We intend to offer the most cost-effective and biologically efficient treatment to capture the majority of that market."

Now, let's see..door number two looks interesting!

exten.com


Share Recommend | Keep | Reply | Mark as Last Read

To: Shawn Donahue who wrote (782)2/16/2000 11:14:00 PM
From: Shawn Donahue
   of 1063
 
To ALL EXTI investors,

Here is feedback from the Biomedical Conference(see post #782)that EXTI attended...It looks like it may prove fruitful! IMO :)

Shawn

Subj: Biomed conference on Saturday
Date: 00-02-14 19:53:59 EST
From: EXTIXENO
To: STDSAD

Dear Shawn,
Jerry Newmin and I did end up going to part of the Biomed conference on Saturday. It was basically a series of company presentations to/for individual investors, but the lunch keynote speaker, Burrill, gave one very good overview of the changes in the biosciences business environment. He and maybe 3 other people there were ptentially good contacts and we are, have been or will be in touch with them. Thanks again for encouraging us to go.
Barbara L. Corbett

Share Recommend | Keep | Reply | Mark as Last Read

To: Danny Kim who wrote ()2/18/2000 3:11:00 PM
From: YadaBoy
   of 1063
 
Um, anybody noticing what is happening here? Have we made someone's Pick-of-the-day list?

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: YadaBoy who wrote (791)2/18/2000 3:50:00 PM
From: Robert Jones
   of 1063
 
Pretty hard not to notice this kind of a move. I have owned this stock some years, but have only a minimal acquaintance with their technology. With that qualifier, here's what I've learning from performing my due diligence. We have a biotech with a device that's beyond the talking stage. There is evidently a urgent medical need for what this device does. We will be submitting to the FDA for level 1 trials this year. Financing (at least partially) is supposedly in place.

In sum, EXTI appears to be a better position than many other biotech startups I've seen, some of which sell for several dollars per share. Thus, I'm not surprised that people perceive EXTI as a attractive speculation at its recent price levels. Ergo, a runup like we're seeing today. Next week should be interesting!

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Robert Jones who wrote (792)2/21/2000 12:53:00 PM
From: PROLIFE
   of 1063
 
We will be submitting to the FDA for level 1 trials this year

Being involved in drug testing before, isn't it true you could be talking a good length of time between trial and market, assuming the product tested is even approved?

thanks

dan

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)

To: PROLIFE who wrote (793)2/21/2000 2:32:00 PM
From: Robert Jones
   of 1063
 
You're correct on all counts. Certainly, nothing will happen rapidly at the FDA, nor is there any assurance that the device will enjoy sales success when and if it's approved. My only point, and the reason why I have EXTI stock, is that the price/potential ratio here seems inordinately attractive as compared to other development stage biotechs I've seen.

Share Recommend | Keep | Reply | Mark as Last Read


To: PROLIFE who wrote (793)2/22/2000 5:26:00 PM
From: Shawn Donahue
   of 1063
 

Dan,

FDA approval is of course for clinical applications, but EXTI is also developing
the SybiolR for Pharmaceutical companes to use as a safe (better than using humans
as guinea pigs, imo), and inexpensive way to test new drugs and this would not require FDA approval...

Message 12667583

Pre-clinical and clinical trials will be directed toward FDA approval for clinical
applications in the US. Sybiol© could also provide pharmaceutical companies
with a safe, inexpensive way to test new drugs, an application which may
not require FDA approval.


Below is also a post from another EXTI investor that sees the potential for SybiolR, even before FDA approval:

Message 12579163



"if we can just demonstrate a device that works in Phase I trials or Phase I & II, I think we would discover that large companies with deep pockets would then become very interested in either acquiring our company or, at least,acquiring our intellectual property rights"

I hope that this helps,

Shawn




Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Shawn Donahue who wrote (795)2/22/2000 6:30:00 PM
From: Danny Kim
   of 1063
 
Hey All, what a great run. I am seeing EXTI cited on many websites, including the rumor mill. This has a lot of steam left! Been holding on snce .04 days waaaay back and will continue to hold in to the tens. They have solid management that will carry them through. Good luck.


Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)

To: Danny Kim who wrote (796)2/22/2000 10:43:00 PM
From: P.S.N.
   of 1063
 
Anybody else notice that the bid is at .63 and the ask is at .62? Anybody else find this strange?
PSN

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: P.S.N. who wrote (797)2/23/2000 12:43:00 AM
From: Karl Zetmeir
   of 1063
 
I think in an effort to thwart the day trader "bandits" ... the exchanges have made a different procedure in the way and timing they change the Bid and Ask.

They were in mid change when the close of biz came.

That's my opinion anyway.

Still ... I'd love to see another gap up tomorrow morning.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)
Previous 10 | Next 10 

Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.